Eisai Co. Ltd.
www.eisai.com
Latest From Eisai Co. Ltd.
Job Cuts As Polyphor Focuses On First-In-Class Anticancer
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
As Belviq Goes Off India Market, Patent Case May Fizzle
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
-
Haruo Naito, Pres. & CEO
Ryohei Yanagi, CFO
Edward Stewart Geary, CMO - Contact Info
-
Eisai Co. Ltd.
Phone: (81) 3 3817 3700
4-6-10 Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice